Research

Retatrutide just took on sleep apnea. The results are hard to sleep on.

Two new phase 3 trials in the New England Journal of Medicine found big drops in nightly breathing interruptions, plus serious weight loss. Here is what they showed.

Retatrutide just took on sleep apnea. The results are hard to sleep on.

What happened

On October 21, 2026, the New England Journal of Medicine published two phase 3 trials testing retatrutide in people with moderate to severe obstructive sleep apnea.

Sleep apnea is when your airway keeps closing during the night, so your breathing stops and starts over and over. Doctors track it with a number called the AHI: how many of those breathing interruptions happen per hour of sleep.

The trials, called TRIUMPH-1-OSA and TRIUMPH-2-OSA, followed 691 adults for 80 weeks. One group did not have type 2 diabetes. The other did.

The numbers

People started out in rough shape, averaging around 56 to 59 breathing interruptions an hour. That counts as severe.

In the trial without diabetes, the top-dose group dropped by about 34 interruptions an hour, compared with about 10 on placebo. In the diabetes trial, the higher doses dropped by about 25, versus about 10 on placebo.

About half of the top-dose group without diabetes ended up with no sleep apnea or only mild sleep apnea without daytime sleepiness, compared with roughly 1 in 8 on placebo, according to the published trial results reported by Medscape.

And the weight loss came along for the ride: up to about 22% average body weight lost in the trial without diabetes, versus about 5% on placebo.

Why it's a big deal

Sleep apnea is incredibly common, and a lot of people hate sleeping with a CPAP mask. A weekly shot that tackles the problem at one of its roots, extra weight, is a big deal for those people.

It also adds to a growing pile of retatrutide wins. This comes right after the main TRIUMPH obesity and diabetes results were published in September.

Lilly has said it plans to ask the FDA for approval in the first quarter of 2027.

The fine print

Retatrutide is still investigational. It is not approved anywhere, and anything sold online as "reta" is not the product tested in these trials.

Side effects were mostly gastrointestinal, like nausea, diarrhea and constipation. Most people in every group, including placebo, reported some kind of side effect.

The trials were funded by Eli Lilly. They measured breathing during sleep, not long-term heart outcomes, so nobody knows yet whether these changes mean fewer heart problems down the road.

This is education, not medical advice. If you snore hard, wake up exhausted, or think you might have sleep apnea, a licensed clinician and a sleep study are the place to start.

Free download

Get the free Peptide Playbook, plus new breakthroughs as they happen.

What peptides are, why people are using them, and what results people are talking about, in plain English. Sign up and we email you the Playbook right away.

Free. Unsubscribe anytime.

  • The Peptide Playbook, free in your inbox
  • Occasional updates on new developments
  • No spam, unsubscribe anytime